RecruitingAchondroplasia
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
Eligible age
3–10 yrs
Accepts
All genders
Locations
8 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Sponsor: Tyra Biosciences, Inc
You may qualify if…
- ✓ Aged 3 to 10 years old (inclusive) at the time of consent.
- ✓ Informed consent provided by parent(s) or legal guardian(s). As study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required).
- ✓ Molecular diagnosis of achondroplasia (FGFR3 G380R).
- ✓ Radiographically confirmed open growth plates at Screening, as determined by bone age X-ray.
- ✓ Able to stand and ambulate independently.
- ✓ Able to take oral medication.
- ✓ Sentinel Safety Cohort only: aged 5 to 10 years old (inclusive).
- ✓ Cohort 1 only: aged 3 to 10 years old (inclusive) and are naive to prior growth accelerating therapy.
You may not qualify if…
- ✕ Presence or history of any concurrent disease or condition that would interfere with study participation, safety evaluations, or any uncontrolled or untreated condition that could impact pediatric growth.
- ✕ Diagnosis of endocrine condition that alters calcium/phosphate homeostasis.
- ✕ Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study.
- ✕ Taking medications that are strong inhibitors or inducers of cytochrome P450 (Cyp) 3A4.
- ✕ History or current evidence of corneal or retinal disorder/keratopathy.
- ✕ Presence of guided growth hardware/8 plates. Planned or anticipated orthopedic surgeries.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06842355 · last updated 2026-06-09